Use of Glidesheath Slender to Reduce Radial Artery Occlusion and Vascular Access Site Complications Following Transradial Coronary Angiography (CAPITAL-PRO)

January 27, 2022 updated by: Aun Yeong Chong, Ottawa Heart Institute Research Corporation
The objective of this study is to determine the rate of radial artery occlusion and vascular access site complications following transradial angiogram using a new Terumo (Tokyo, Japan) Glidesheath Slender, in comparison with the currently used 6 French (6 Fr.) radial sheath.

Study Overview

Detailed Description

Based on previously reported studies the rates of radial artery occlusion using a standard 6 Fr. sheath is around 5-10%, compared to the single feasibility study of the Glidesheath Slender by Aminian et al (see reference in the citations), the rate of radial artery occlusion was reported 0.88%.

This study will be a prospective randomized, single-blinded (patient-blinded) study, comparing the rate of radial artery occlusion and vascular access site complications between the Glidesheath Slender (Terumo, Tokyo, Japan) and the standard 6 Fr. radial sheath in patients undergoing transradial coronary catheterization.

  • The study will enroll patients who will undergo elective or emergency coronary angiography and/or percutaneous coronary intervention (PCI) via transradial approach at the University of Ottawa Heart Institute.
  • A baseline clinical vascular & ultrasound assessment will be performed prior to the procedure to document patency of the radial artery.
  • Patients will be randomized in 1:1 fashion to either receive the Terumo Glidesheath Slender versus the currently used 6 Fr. sheath.
  • The standard angiogram/ PCI will be performed as per usual practice.
  • Following the angiogram, clinical vascular assessment as well as an ultrasound will be performed prior to discharge.
  • At 30 days follow up the patient will come back for clinical and ultrasound assessment of radial artery patency and access site vascular complications.

Study Type

Interventional

Enrollment (Anticipated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Ottawa, Ontario, Canada, K1Y 4W7
        • University of Ottawa Heart Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing coronary angiography and/or PCI via transradial approach
  • Informed consent
  • Documented normal Allen's test

Exclusion Criteria:

  • Patient who had a previous angiogram using the same radial artery
  • Abnormal Allen's test
  • Previous failed radial access.
  • Known bleeding disorder or hypercoagulable condition
  • Cardiogenic shock

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Glidesheath Slender
The transradial procedure will be performed using the glidesheath slender (studied sheath)
testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
Other Names:
  • Glidesheath Slender, Terumo, Tokyo, Japan
Active Comparator: Standard sheath
The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radial artery occlusion
Time Frame: 30 days
Evaluated clinically and by ultrasound
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vascular access site complications
Time Frame: up to 30 days
Includes: Radial artery occlusion, bleeding or hematoma, pseudoaneurysm, artery dissection, compartment syndrome of the forearm
up to 30 days
Radial artery spasm
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 day
participants will be followed for the duration of hospital stay, an expected average of 1 day
Procedure success
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 day
Defined as ability to finish the angiogram/PCI via the intended access site, without the need to change access site.
participants will be followed for the duration of hospital stay, an expected average of 1 day
Sheath kinking
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 day
Major requiring sheath exchange or minor
participants will be followed for the duration of hospital stay, an expected average of 1 day
Painful sheath removal
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 day
Scored on a scale of 1-10 scoring system
participants will be followed for the duration of hospital stay, an expected average of 1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Aun-Yeong Chong, MRCP, MD, University of Ottawa Heart Institute Research Corporation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2014

Primary Completion (Actual)

March 1, 2019

Study Completion (Actual)

March 21, 2019

Study Registration Dates

First Submitted

December 8, 2014

First Submitted That Met QC Criteria

December 23, 2014

First Posted (Estimate)

December 24, 2014

Study Record Updates

Last Update Posted (Actual)

January 28, 2022

Last Update Submitted That Met QC Criteria

January 27, 2022

Last Verified

January 1, 2022

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Heart Disease

Clinical Trials on Glidesheath Slender

3
Subscribe